Roche Holding AG (ROP) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Roche Holding AG (ROP) has a cash flow conversion efficiency ratio of 0.296x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF11.23 Billion ≈ $14.20 Billion USD) by net assets (CHF37.88 Billion ≈ $47.89 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See operational self-sufficiency of Roche Holding AG to measure how many days the company can operate on defensive assets alone.
Roche Holding AG - Cash Flow Conversion Efficiency Trend (1998–2025)
This chart illustrates how Roche Holding AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Roche Holding AG Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Roche Holding AG ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
AstraZeneca PLC
F:ZEGA
|
0.112x |
|
Toyota Motor Corporation ADR
NYSE:TM
|
0.021x |
|
UnitedHealth Group Incorporated
NYSE:UNH
|
0.011x |
|
Roche Holding AG
SW:ROG
|
0.296x |
|
Qualcomm Incorporated
NASDAQ:QCOM
|
0.090x |
|
China Construction Bank Corporation
F:C6T
|
0.158x |
|
Westpac Banking Corporation
AU:WBCPI
|
-0.064x |
|
KLA Corporation
NASDAQ:KLAC
|
0.121x |
Annual Cash Flow Conversion Efficiency for Roche Holding AG (1998–2025)
The table below shows the annual cash flow conversion efficiency of Roche Holding AG from 1998 to 2025. For the full company profile with market capitalisation and key ratios, see market value of Roche Holding AG.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CHF37.88 Billion ≈ $47.89 Billion |
CHF17.83 Billion ≈ $22.54 Billion |
0.471x | -15.29% |
| 2024-12-31 | CHF36.16 Billion ≈ $45.72 Billion |
CHF20.09 Billion ≈ $25.40 Billion |
0.556x | +14.84% |
| 2023-12-31 | CHF33.26 Billion ≈ $42.05 Billion |
CHF16.09 Billion ≈ $20.35 Billion |
0.484x | -13.41% |
| 2022-12-31 | CHF32.02 Billion ≈ $40.48 Billion |
CHF17.89 Billion ≈ $22.62 Billion |
0.559x | -22.99% |
| 2021-12-31 | CHF28.34 Billion ≈ $35.84 Billion |
CHF20.57 Billion ≈ $26.00 Billion |
0.726x | +58.93% |
| 2020-12-31 | CHF39.77 Billion ≈ $50.28 Billion |
CHF18.16 Billion ≈ $22.96 Billion |
0.457x | -26.84% |
| 2019-12-31 | CHF35.87 Billion ≈ $45.35 Billion |
CHF22.39 Billion ≈ $28.30 Billion |
0.624x | -5.14% |
| 2018-12-31 | CHF30.37 Billion ≈ $38.39 Billion |
CHF19.98 Billion ≈ $25.26 Billion |
0.658x | +5.89% |
| 2017-12-31 | CHF29.01 Billion ≈ $36.67 Billion |
CHF18.02 Billion ≈ $22.79 Billion |
0.621x | +9.36% |
| 2016-12-31 | CHF26.40 Billion ≈ $33.38 Billion |
CHF15.00 Billion ≈ $18.97 Billion |
0.568x | -13.20% |
| 2015-12-31 | CHF23.30 Billion ≈ $29.46 Billion |
CHF15.25 Billion ≈ $19.28 Billion |
0.655x | -11.42% |
| 2014-12-31 | CHF21.56 Billion ≈ $27.26 Billion |
CHF15.93 Billion ≈ $20.14 Billion |
0.739x | -0.48% |
| 2013-12-31 | CHF21.24 Billion ≈ $26.85 Billion |
CHF15.77 Billion ≈ $19.94 Billion |
0.743x | -17.22% |
| 2012-12-31 | CHF16.73 Billion ≈ $21.15 Billion |
CHF15.01 Billion ≈ $18.97 Billion |
0.897x | +0.28% |
| 2011-12-31 | CHF14.48 Billion ≈ $18.31 Billion |
CHF12.95 Billion ≈ $16.38 Billion |
0.894x | -27.27% |
| 2010-12-31 | CHF11.66 Billion ≈ $14.74 Billion |
CHF14.34 Billion ≈ $18.13 Billion |
1.230x | -31.40% |
| 2009-12-31 | CHF9.41 Billion ≈ $11.90 Billion |
CHF16.88 Billion ≈ $21.34 Billion |
1.793x | +692.39% |
| 2008-12-31 | CHF53.82 Billion ≈ $68.05 Billion |
CHF12.18 Billion ≈ $15.40 Billion |
0.226x | +2.83% |
| 2007-12-31 | CHF53.31 Billion ≈ $67.39 Billion |
CHF11.73 Billion ≈ $14.83 Billion |
0.220x | -0.29% |
| 2006-12-31 | CHF46.81 Billion ≈ $59.19 Billion |
CHF10.33 Billion ≈ $13.06 Billion |
0.221x | -7.67% |
| 2005-12-31 | CHF41.74 Billion ≈ $52.77 Billion |
CHF9.97 Billion ≈ $12.61 Billion |
0.239x | +8.46% |
| 2004-12-31 | CHF33.29 Billion ≈ $42.09 Billion |
CHF7.33 Billion ≈ $9.27 Billion |
0.220x | -11.41% |
| 2003-12-31 | CHF29.16 Billion ≈ $36.87 Billion |
CHF7.25 Billion ≈ $9.17 Billion |
0.249x | +552.72% |
| 2002-12-31 | CHF25.77 Billion ≈ $32.58 Billion |
CHF982.00 Million ≈ $1.24 Billion |
0.038x | -74.64% |
| 2001-12-31 | CHF33.87 Billion ≈ $42.82 Billion |
CHF5.09 Billion ≈ $6.43 Billion |
0.150x | +22.90% |
| 2000-12-31 | CHF32.04 Billion ≈ $40.50 Billion |
CHF3.92 Billion ≈ $4.95 Billion |
0.122x | +112.35% |
| 1999-12-31 | CHF30.00 Billion ≈ $37.93 Billion |
CHF1.73 Billion ≈ $2.18 Billion |
0.058x | -63.69% |
| 1998-12-31 | CHF22.82 Billion ≈ $28.84 Billion |
CHF3.62 Billion ≈ $4.57 Billion |
0.159x | -- |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and tr… Read more